IRLAB Therapeutics AB Class A (0GFH) AI Stock Analysis

IRLAB Therapeutics AB Class A

(LSE:0GFH)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved Balance SheetLeverage has improved materially from prior years, reducing balance-sheet risk and providing greater financial flexibility. The roughly 97M equity base offers some cushion while IRLAB continues funding clinical development, although persistent losses could gradually weaken that support.

Negative Factors

Deep UnprofitabilityDeep losses and a shrinking top line show that the current business has not yet reached the scale needed to cover its cost base. Continued unprofitability can consume capital, limit development choices, and make future progress dependent on successful pipeline advancement.

IRLAB Therapeutics AB Class A Business Overview & Revenue Model

Company Description

IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat,...

IRLAB Therapeutics AB Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0GFH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SANION	77Outperform	SEK 1.54B	8.30	29.71%	―	24.98%	-31.44%
SE:BIOA.B	65Neutral	SEK 28.15B	266.55	5.18%	0.68%	-46.09%	-90.13%
SE:SYNACT	57Neutral	SEK 911.79M	-8.23	-58.12%	―	―	1.42%
SE:ALZCUR	55Neutral	SEK 882.54M	42.87	65.99%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZ	44Neutral	SEK 112.04M	-1.68	-17.52%	―	-100.00%	20.94%

* Healthcare Sector Average

Performance Comparison

GB:0GFH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ALZ	Alzinova AB	0.35	-1.07	-75.14%
SE:ALZCUR	AlzeCure Pharma AB	6.40	4.54	243.16%
SE:BIOA.B	BioArctic AB Class B	317.20	34.68	12.27%
SE:SYNACT	SynAct Pharma AB	16.22	-6.68	-29.17%
SE:SANION	Saniona AB	11.13	-5.17	-31.72%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

IRLAB Therapeutics AB Class A AI Stock Analysis